Evidence map›Paper›PMID 40824466›Full record

ReviewDiscover nano2025

Applications of nanomaterials in head and neck squamous cell carcinoma: current progress and perspectives.

Guo Cheng, Wentao Li, Xin Zhu, Chenping Zhang

Abstract readReview
In one paragraph

Review in Discover nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Guo ChengProvincial Key Laboratory of Precision Medicine Research On Head & Neck Cancer, Zhejiang Cancer Hospital, Hangzhou, China.
Wentao LiProvincial Key Laboratory of Precision Medicine Research On Head & Neck Cancer, Zhejiang Cancer Hospital, Hangzhou, China.
Xin ZhuProvincial Key Laboratory of Precision Medicine Research On Head & Neck Cancer, Zhejiang Cancer Hospital, Hangzhou, China. zhuxin@zjcc.org.cn.
Chenping ZhangProvincial Key Laboratory of Precision Medicine Research On Head & Neck Cancer, Zhejiang Cancer Hospital, Hangzhou, China. zhangcp@zjcc.org.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Head and neck squamous cell carcinoma (HNSCC) is a common malignant tumor that affects the head and neck area. HNSCC typically has complex clinical symptoms and is detected at a late stage. Therefore, it is quite difficult to give patients the best possible care and treatment. Faced with these challenges, nanomaterials are receiving increasing attention in the biomedical field due to their unique structural and physicochemical properties. The application of nanomaterial therapeutics has produced innovative HNSCC treatment options that go beyond the constraints of conventional surgery, radiation therapy, and chemotherapy. In this review, we first reviewed the pathological mechanisms of HNSCC. Subsequently, a detailed introduction to nanomaterials was given, including their classification and definition. Then, the use of nanomaterials in the diagnosis and therapy of HNSCC was discussed, and incorporating the perspective of organoids and clinical trials to increase the feasibility of nanomaterial applications. In addition, we also reviewed the advantages and disadvantages of nanomaterials, proposed the idea of nanomaterial design, looking at how these properties may be used to improve our understanding and treatment of HNSCC. The present approaches for detecting and treating HNSCC can be improved by integrating the special qualities of nanomaterials with the available therapeutic modalities. This will eventually enhance patient outcomes in the battle against this highly invasive malignant tumor.

Identifiers

PMID40824466
PMCPMC12361023

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.